Advertisement

Topics

Sugammadex Hypersensitivity Study (Study P06042)(COMPLETED)

2014-08-27 03:18:57 | BioPortfolio

Summary

This trial is being conducted to study the potential for hypersensitivity symptoms at the time of initial exposure to sugammadex and upon repeat exposure, since it is unknown whether the frequency or severity of hypersensitivity symptoms may worsen at repeat exposure over a prolonged period.

Participants will be randomized to receive one of three study treatments: sugammadex 4 mg/kg, sugammadex 16 mg/kg, or placebo. Participants will receive one dose of study treatment on Day 8, Day 36, and Day 78 of the study in order to determine the safety of each treatment dose.

Description

To ensure safety of the participants, all participants will be admitted to the study center the day before each scheduled dose and will leave the unit the morning of the day after each dose. In cases of suspected hypersensitivity symptoms, participants will remain confined to the study center until all signs and symptoms regress, the participant is stable and the investigator considers it safe for the participant to leave the study center.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Hypersensitivity

Intervention

Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Placebo

Status

Completed

Source

Schering-Plough

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:18:57-0400

Clinical Trials [250 Associated Clinical Trials listed on BioPortfolio]

Dose-Finding Pediatric Trial With Sugammadex (19.4.306)(P05961)(COMPLETED)

The purpose of this study is: - to explore the dose-response relation of sugammadex given as a reversal agent at reappearance of T2 after 0.6 mg.kg-1 rocuronium in pediatric and a...

Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)(COMPLETED)

The purpose of this study is to determine the optimal dose of sugammadex when this compound is administered during deep neuromuscular block. Sugammadex is administered shortly (5 minutes) ...

The Effect of Sugammadex on the Outcome After Colorectal Cancer Surgery

This study is retrospective study. The purpose of this study is checking the effect of sugammadex on the outcome after colorectal surgery. The outcome is compared among the 2 groups, sugam...

Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery

The purpose of this study is to learn if there is a difference in recovery time when using sugammadex versus neostigmine. The researchers also hope to add further knowledge and data to the...

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

Sugammadex or neostigmine are given at the end of the surgery to reverse neuro muscular blocking drugs. This study will evaluate whether reversal of NMBD with sugammadex is associated with...

PubMed Articles [1124 Associated PubMed Articles listed on BioPortfolio]

Anaphylactic shock after sugammadex administration, induced by formation of a sugammadex-rocuronium complex.

A 42-year-old man developed anaphylactic shock in the postanesthesia care unit. Initially, sugammadex, a reversal agent for a non-depolarizing neuromuscular blocking agent, was suspected as the causat...

Monitoring of Sugammadex Dosing at a Large Tertiary Care Pediatric Hospital.

Anesthesiologists use sugammadex to reverse neuromuscular blockade (NMB) produced by rocuronium and vecuronium. Its mechanism involves encapsulation of the neuromuscular blocking agent. Sugammadex dos...

Reversal of Deep Pipecuronium-Induced Neuromuscular Block With Moderate Versus Standard Dose of Sugammadex: A Randomized, Double-Blind, Noninferiority Trial.

Certain surgical interventions may require a deep neuromuscular block (NMB). Reversal of such a block before tracheal extubation is challenging. Because anticholinesterases are ineffective in deep blo...

Comparison of the cytotoxic, genotoxic and apoptotic effects of Sugammadex and Neostigmine on human embryonic renal cell (HEK-293).

Acetylcholinesterase inhibitors, including Neostigmine, have been used to reverse neuromuscular blockage for many years. Sugammadex reverses this blockage using its gamma cyclodextrin ring, a mechanis...

Differences of Recovery from Rocuronium-induced Deep Paralysis in Response to Small Doses of Sugammadex between Elderly and Nonelderly Patients.

WHAT THIS ARTICLE TELLS US THAT IS NEW: BACKGROUND:: Complete recovery from rocuronium-induced muscle paralysis with sugammadex is reported to be delayed in elderly patients. The authors tested a hypo...

Medical and Biotech [MESH] Definitions

Allergic reaction to products containing processed natural rubber latex such as rubber gloves, condoms, catheters, dental dams, balloons, and sporting equipment. Both T-cell mediated (HYPERSENSITIVITY, DELAYED) and IgE antibody-mediated (HYPERSENSITIVITY, IMMEDIATE) allergic responses are possible. Delayed hypersensitivity results from exposure to antioxidants present in the rubber; immediate hypersensitivity results from exposure to a latex protein.

Antigen-type substances that produce immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).

Epicutaneous or intradermal application of a sensitizer for demonstration of either delayed or immediate hypersensitivity. Used in diagnosis of hypersensitivity or as a test for cellular immunity.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

A form of hypersensitivity affecting the respiratory tract. It includes ASTHMA and RHINITIS, ALLERGIC, SEASONAL.

More From BioPortfolio on "Sugammadex Hypersensitivity Study (Study P06042)(COMPLETED)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Trial